Gencove
Private Company
Total funding raised: $12.8M
Overview
Founded in 2015, Gencove has developed a proprietary low-pass sequencing platform that offers a cost-effective alternative to traditional genotyping microarrays, enabling scalable whole-genome analysis. The company operates a dual business model, serving enterprise research and pharmaceutical partners while also marketing a direct-to-consumer health product. Its technology is positioned to become a standard in research and diagnostics by providing more comprehensive genetic data that supports reanalysis as science evolves.
Technology Platform
Low-pass whole genome sequencing (LP-WGS) and bioinformatics platform for generating polygenic risk scores and genomic insights across species.
Funding History
3Opportunities
Risk Factors
Competitive Landscape
Competes with DTC giants (23andMe, AncestryDNA) using microarrays, and with other sequencing-based services (Nebula Genomics, Dante Labs). In the enterprise space, competes with genotyping array providers (Illumina, Thermo Fisher) and other low-pass sequencing analytic firms. Differentiation hinges on the cost-effectiveness and data richness of its low-pass sequencing platform.